Tesamorelin | Luxbae Peptide Therapy

Home › Peptides › Tesamorelin
GHRH Analogue · Visceral Fat

Tesamorelin Visceral-Fat GHRH

The FDA-approved GHRH analogue (Egrifta) with documented visceral adipose reduction in clinical trials.

Book Free ConsultationCall 310.299.4444

What Tesamorelin actually is

Tesamorelin is a stabilized GHRH (1-44) analogue with a trans-3-hexenoyl modification at the N-terminus that protects against DPP-IV degradation. It is FDA-approved as Egrifta for the reduction of excess abdominal fat in HIV-associated lipodystrophy.1

Falutz and colleagues demonstrated significant reductions in visceral adipose tissue measured by CT in pivotal trials — the strongest randomized evidence of any GHRH analogue for body composition.2 At Luxbae, Tesamorelin is prescribed off-label for adults with central adiposity who want a peptide with documented visceral-fat selectivity.

At Luxbae, Tesamorelin is prescribed and supervised by Dr. Ernst von Schwarz, MD, PhD after a complimentary medical consultation.

Mechanism — Visceral adipose selectivity

Sustained pulsatile GH release drives lipolysis in visceral depots preferentially over subcutaneous fat in randomized data.2

What the research shows

Documented VAT reduction. Significant decreases in visceral adipose tissue on CT in randomized trials.2

Triglyceride improvement. Lipid profile shifts reported alongside VAT reduction.3

IGF-1 elevation. Predictable IGF-1 increase to upper-normal range.

Side effects: Injection-site reactions, peripheral edema, arthralgias, glucose elevation in pre-diabetics, occasional paresthesias.

FDA note: FDA-approved as Egrifta for HIV-associated lipodystrophy. Off-label use for general adiposity is at physician discretion under medical supervision.

Tesamorelin FAQ

Is this better than CJC for fat loss?
For visceral fat specifically — yes. Randomized trial data favors Tesamorelin.

Will I lose subcutaneous fat too?
Less selectively. The signal is strongest in visceral compartments.

References

  1. Egrifta (tesamorelin) Prescribing Information. FDA-approved label. 2010.
  2. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in HIV lipodystrophy. N Engl J Med. 2007;357(23):2359-2370.
  3. Stanley TL, Falutz J, et al. Effects of tesamorelin on inflammatory markers in HIV lipodystrophy. AIDS. 2011.

Start your Tesamorelin protocol at Luxbae

Call 310.299.4444Book Online
Medical disclaimer: This is educational information, not medical advice. Tesamorelin is investigational and many uses are not FDA-approved; treatments at Luxbae are administered under medical supervision by Dr. Ernst von Schwarz. Individual results vary.
Scroll to Top